Edwards Lifesciences on Thursday said that a federal jury in Boston has awarded it $70 million in damages for trade secret misappropriation in a suit Edwards inherited from its $400 million acquisition of CardiAQ last year.
CardiAQ—which has a transcatheter mitral valve replacement system, a super hot area in medtech—had accused a former service provider, Neovasc, of breaching the non-disclosure agreement between the parties and misappropriating trade secrets. The federal jury agreed.
CardiAQ—which has a transcatheter mitral valve replacement system, a super hot area in medtech—had accused a former service provider, Neovasc, of breaching the non-disclosure agreement between the parties and misappropriating trade secrets. The federal jury agreed.
